PPCB
NASD Propanc Biopharma Inc$0.5075 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.5075, $0.0225 below the day’s high of $0.5300
- YTD change
- -96.22%
- vs 20-day SMA
- -30.67%
- vs 200-day SMA
- -86.80%
Price ranges
Price & Performance
+0.40 (+353.12%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.8% away from all-time highs of $275.0000
- PPCB is down 96% since the beginning of the year
- PPCB is down 99% over the past 12 months
- PPCB is down 51% over the past 1 month
- 0% of all PPCB investors are betting against PPCB
PPCB reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -71.3%.
- Previous minute
- -$0.0040
- Last hour
- +$0.0000
- Last 5 days
- -15.67%
- vs 8-day SMA
- -10.80%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.